Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study

Shengming Jin; Shengming Jin; Jiaming Wei; Jiaming Wei; Junjie Wang; Junjie Wang; Beihe Wang; Beihe Wang; Junlong Wu; Junlong Wu; Hualei Gan; Hualei Gan; Bo Dai; Bo Dai; Xiaojian Qin; Xiaojian Qin; Guowen Lin; Guowen Lin; Yu Wei; Yu Wei; Chen Yang; Yijun Shen; Yijun Shen; Yiping Zhu; Yiping Zhu; Yao Zhu; Yao Zhu; Dingwei Ye; Dingwei Ye

doi:10.3389/fonc.2020.527952

Frontiers in Oncology (Dec 2020)

Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study

Shengming Jin,
Shengming Jin,
Jiaming Wei,
Jiaming Wei,
Junjie Wang,
Junjie Wang,
Beihe Wang,
Beihe Wang,
Junlong Wu,
Junlong Wu,
Hualei Gan,
Hualei Gan,
Bo Dai,
Bo Dai,
Xiaojian Qin,
Xiaojian Qin,
Guowen Lin,
Guowen Lin,
Yu Wei,
Yu Wei,
Chen Yang,
Yijun Shen,
Yijun Shen,
Yiping Zhu,
Yiping Zhu,
Yao Zhu,
Yao Zhu,
Dingwei Ye,
Dingwei Ye

Affiliations

Shengming Jin: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Shengming Jin: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Jiaming Wei: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Jiaming Wei: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Junjie Wang: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Junjie Wang: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Beihe Wang: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Beihe Wang: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Junlong Wu: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Junlong Wu: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Hualei Gan: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Hualei Gan: Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Bo Dai: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Bo Dai: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Xiaojian Qin: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Xiaojian Qin: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Guowen Lin: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Guowen Lin: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Yu Wei: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Yu Wei: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Chen Yang: Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
Yijun Shen: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Yijun Shen: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Yiping Zhu: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Yiping Zhu: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Yao Zhu: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Yao Zhu: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Dingwei Ye: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Dingwei Ye: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

DOI: https://doi.org/10.3389/fonc.2020.527952
Journal volume & issue: Vol. 10

Abstract

Read online

PurposeOur study aims to examine the impact of definitive local therapy in prostate cancer patients with different metastatic sites.MethodsTotally, 5,849 patients diagnosed with metastatic prostate carcinoma from 2010 to 2014 were selected from Surveillance, Epidemiology, and End Results (SEER). Log-rank analyses, multivariable regression analysis, and Kaplan–Meier methods were used to assess prognostic impact of local treatment in patients with different metastatic sites. Survival curves and forest plots were also plotted to describe the prognostic value of definitive local therapy.ResultsIn our study, 159 patients received radical prostatectomy, and 62 received brachytherapy, while 5,628 did not receive local definitive local therapy. Survival analysis revealed that patients who received definitive local therapy had a better 5-year overall survival (OS) (P = 0.011) and cancer-specific survival (CSS) (P = 0.012). Multivariate regression analyses demonstrated that type of treatment was an independent prognostic indicator for OS (P = 0.011) and CSS (P = 0.012), along with age at diagnosis, chemotherapy, PSA level, and Gleason score. According to subgroup analysis, patients with bone metastasis or distant lymph node (LN) metastasis were significantly more likely to benefit from definitive local therapy. In addition, forest plots demonstrated that RP group had significant favorable OS and CSS in subgroups of younger age at diagnosis, T2–3 stage, N0–1 stage, Gleason score =7 or ≥8, bone metastasis, and distant LN metastasis.ConclusionsOur study suggested that local therapy improved survival in prostate cancer patients with bone or distant LN metastasis. Furthermore, patients who were at T2–3 stage or Gleason score ≥7 also significantly benefit from definitive local therapy.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords